Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Trillium Therapeutics -- Ignore unavailable to you. Want to Upgrade?

To: semi_infinite who wrote (233)	11/13/2018 4:59:34 PM
From: ghmm	Respond to of 294

I can join you as I added more recently thinking there is not much downside but I was wrong :). Its hard to understand what management is thinking. They obviously need (much) more capital to advance the program and it would be better served in the hands of a much bigger partner who has the means to try various combinations and indications. With the market cap where it is I I don't know how they go it alone anymore I guess they could do a rights offering which seems is more popular in Canada. I would just as soon see an activist push to sell the company now rather than try to add value advancing since management has done a poor job.